VEGF and PEDF in Patients With Myopic Choroidal Neovascularization

Completed

• Conditions: Myopic Choroidal Neovascularization; VEGF Aqueous Level; PEDF Aqueous Level

• Registration Number: NCT02175940
• Lead Sponsor: Università degli Studi di Brescia

Brief Summary

This was a prospective, case-control study investigating aqueous levels of VEGF and PEDF in eyes with mCNV treated with IVB.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-07
• Primary Completion: 2014-01
• Study Completion: 2014-05
• Status Verified: 2014-06
• Study First Submitted: 2014-06-24
• Study First Submitted QC: 2014-06-25
• Last Update Submitted: 2014-06-25
• Study First Posted: 2014-06-26
• Last Update Posted: 2014-06-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• pathologic myopia, defined as spherical equivalent >6 diopters and axial length >26 mm
• posterior pole myopic retinal changes (posterior staphyloma, chorioretinal atrophy, papillary crescent);
• fluorescein angiography, indocyanine green angiography and optical coherence tomography detection of the subfoveal or juxtafoveal choroidal neovascularization
• clear ocular media;

Exclusion Criteria

• previous treatment for choroidal neovascularization, including the previous intravitreal drug injection or PDT
• presence of other maculopathy as diabetic retinopathy or retinal vascular occlusion
• history of recent myocardial infarction or other thromboembolic events
• ongoing uncontrolled hypertension or glaucoma
• refractive media opacities
• previous eye surgery

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
vascular endothelial growth factor (VEGF) aqueous levels	2 months	VEGF aqueous levels before and after intravitreal ranibizumab
pigment epithelium-derived factor (PEDF) aqueous levels	2 months	PEDF aqueous levels before and after intravitreal ranibizumab

Secondary Outcome Measures

Name	Time	Method
best-corrected visual acuity	2 months
central retinal thickness	2 months

Trial Locations

Locations (1)

Medical Retina Department, University of Molise; 🇮🇹 Cambpobasso, CB, Italy